Cancer patients who immunized with two doses of ChAdOx1 nCoV-19 (viral vector) or CoronaVac (inactivated virus) COVID-19 vaccines Immunogenicity, seroconversion rate, COVID-19 vaccine, cancer patients
Conditions
Interventions
The chemotherapy group was defined as those patients who received their first dose of COVID-19 vaccine while undergoing cytotoxic chemotherapy treatment or within 1 month from their last dose of chemo
Prevention,Prevention
cancer patients receiving chemotherapy treatment,cancer patients receiving non-chemotherapy treatment
Sponsors
Chulabhorn Royal Academy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients were eligible if they were Thai citizens aged 18 years or older with histologically or cytologically confirmed solid malignancy, in either early or advanced stages. Other inclusion criteria were an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 3 and currently receiving systemic anticancer therapy or active surveillance/follow-up within five years after completed cancer treatment.
Exclusion criteria
Exclusion criteria: Hematologic malignancy, Concurrent chemoradiotherapy, absolute neutrophil count of less than 1500 cells per mcl or platelet count of less than 100,000 per mcl, expected life expectancy of less than 3 months, HIV infection, pregnancy, and breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The immunogenicity of COVID-19 vaccine 6 months Anibody level | — |
Secondary
| Measure | Time frame |
|---|---|
| the anti-SARS-CoV-2 S antibody seroconversion rate 6 months A proportion,Safety 7 days A proportion,the effects of the COVID-19 vaccine type on the anti-SARS-CoV-2 S antibody titer 6 months Antibody level,the effects of the COVID-19 vaccine type on the seroconversion rate 6 months A proportion | — |
Countries
Thailand
Contacts
Public ContactChayanee Samdaengpan
Chulabhorn
Outcome results
None listed